Journal of Infectious Diseases & Therapy
Open Access

Efficacy and Safety of AKT Inhibitors in HR+/HER2- Breast Cancer or Metastatic TNBC: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Wuzhi Zhong¹, Tao Yan¹, Lehui Li¹, Xinguang Zhang¹, Ru Zhang¹, Dijia Li¹, Lijie Ma¹, Chunfa Zhang¹, Ya Wang¹, Xiaodong Cao¹, Nan Zhang¹ and Ziying Zhang^1,2*

¹Department of Medical Oncology, Basic Medicine College, Inner Mongolia Medical University, Hohhot, Inner Mongolia, China

²Medical Experiment Center, Inner Mongolia Medical University, Hohhot, 010110, China

Received Date: May 03, 2024 / Published Date: Jun 05, 2024

Citation: Zhong W, Yan T, Li L, Zhang X, Zhang R, et al. (2024) Efficacy and Safety of AKT Inhibitors in HR+/HER2- Breast Cancer or Metastatic TNBC: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Infect Dis Ther S7:003.DOI: 10.4173/2332-0877.24.S7.003

Copyright: © 2024 Zhong W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF

Background: This study aims to investigate the impact of AKT inhibitors (Capivasertib and Ipatasertib) on the efficacy and safety of patients with HR+/HER2- breast cancer or metastatic TNBC.

Methods: A comprehensive search for relevant Randomized Clinical Trials (RCTs) of AKT inhibitors were conducted through PubMed, Embase, and Cochrane Library. The meta-analysis included five studies with a total of 1304 patients. Outcome indicators such as Progression-Free Survival (PFS), Adverse Events (AEs), Overall Survival (OS), Duration of Response (DOR), Objective Response Rate (ORR), and Clinical Benefit Rate (CBR) were analyzed using Review Manager 5.4.1.

Results: Patients treated with AKT inhibitors showed a significant improvement in PFS compared to those without (MD=2.39; 95% CI: 1.06, 3.73; p=0.0005; I2=55%). However, the incidence of some dangerous AEs increased, including infection (OR=1.72; 95% CI: 1.09, 2.72; p=0.02; I2=0%) and hyperglycemia (OR=3.07; 95% CI: 1.36, 6.93; p=0.007; I2=63%).

Conclusion: AKT inhibitors significantly prolonged the survival of patients with metastatic TNBC and HR+/HER2- breast cancer. Nevertheless, the occurrence of AEs, such as infection and hyperglycemia, during AKT inhibitor treatment suggests the need for careful and rational drug usage based on specific patient conditions.

Keywords